Metabolic profile differences in ACTH-dependent and ACTH-independent Cushing syndrome

Zhengyang Li1,2 | Chen Zhang1,2 | Chong Geng3 | Yongfeng Song1,2,4

1Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China
2Institute of Endocrinology and metabolism, Shandong Academy of Clinical Medicine, Jinan, Shandong 250021, China
3Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China
4Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China

Correspondence
Chong Geng, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China. Email: llexydfq@163.com

Yongfeng Song, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324#, Jing 5 Road, Jinan, Shandong 250021, China. Email: syf198506@163.com

Edited by Yi Cui

Abstract

Background: The most common etiologies of Cushing’s syndrome (CS) are adrenocorticotropic hormone (ACTH)-producing pituitary adenoma (pitCS) and primary adrenal gland disease (adrCS), both of which burden patients with metabolic disturbance. The aim of this study was to compare the metabolic features of pitCS and adrCS patients.

Methods: A retrospective review including 114 patients (64 adrCS and 50 pitCS) diagnosed with CS in 2009–2019 was performed. Metabolic factors were then compared between pitCS and adrCS groups.

Results: Regarding sex, females suffered both adrCS (92.2%) and pitCS (88.0%) more frequently than males. Regarding age, patients with pitCS were diagnosed at a younger age (35.40 ± 11.94 vs. 39.65 ± 11.37 years, p = 0.056) than those with adrCS, although the difference was not statistically significant. Moreover, pitCS patients had much higher ACTH levels and more serious occurrences of hypercortisolemia at all time points (8 AM, 4 PM, 12 AM) than that in adrCS patients. Conversely, indexes, including body weight, BMI, blood pressure, serum total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose, and uric acid, showed no differences between adrCS and pitCS patients. Furthermore, diabetes prevalence was higher in pitCS patients than in adrCS patients; however, there were no significant differences in hypertension or dyslipidemia prevalence between the two.

Conclusions: Although adrCS and pitCS had different pathogenetic mechanisms, different severities of hypercortisolemia, and different diabetes prevalences, both etiologies had similar metabolic characteristics.

Keywords: adrenal Cushing’s, Cushing’s syndrome, metabolic disturbance, pituitary Cushing’s

1 | INTRODUCTION

Endogenous Cushing’s syndrome (CS) is a rare endocrine disease characterized by endogenous glucocorticoid excess, with an estimated annual incidence of 2–3 cases per million.1 As the name implies, patients affected with CS usually manifest a syndrome of systemic symptoms, including abdominal obesity, impaired glucose tolerance/diabetes, hypertension, hypokalemia, infections, dyslipidemia, and osteoporosis.2 Increased morbidity and mortality among these patients have been attributed to the cardiovascular, thrombotic, metabolic, infectious, and musculoskeletal complications of the disease.3

Pathogenic mechanisms of endogenous CS can be divided into adrenocorticotropic hormone (ACTH)-dependent (accounting for about 70%–80% of cases, due
to a pituitary or other ectopic tumor) and ACTH-independent (accounting for about 20%–30% of cases, due to adrenal benign or malignant nodules, or adrenocortical hyperplasia) causes.1,5 Although both ACTH-dependent and ACTH-independent CS result to endogenous hypercortisolism, ACTH levels of patients differ between the two types of CS. Specifically, ACTH levels are higher in ACTH-dependent CS patients, whereas ACTH levels are lower or can even be undetectable in ACTH-independent CS patients.6 Aside from this difference, only a few studies have actually compared the demographic, clinical, and biochemical variables among patients with different CS etiologies.

In particular, the ERCUSYN Study Group reported that patients belonging in the adrenal CS (adrCS) group were older than those in the pituitary CS (pitCS) group. Hirsutism and diabetes prevalence in the ectopic CS (ectCS) group were also found to be higher than that in the adrCS and pitCS groups. Furthermore, pitCS patients reported more skin alterations, menstrual irregularities, and hirsutism than adrCS patients.7 Another study reported that pitCS patients had a lower prevalence of hypertension, whereas no between-group differences in hypercortisolism were noted.8 Despite the findings of these studies, differences in the metabolic factors of the different etiologies of CS remain unclear.

Therefore, a retrospective study was performed to analyze and compare the metabolic features of pituitary CS (pitCS) and adrenal CS (adrCS) patients.

2  METHODS

2.1  Ethical approval

The study was conducted in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the ethics committee of the Shandong Provincial Hospital. Due to this study's retrospective nature, the need for a written consent was waived.

2.2  Subjects

CS patients who were admitted and diagnosed in Shandong Provincial Hospital, which is affiliated to the Shandong First Medical University, between October 2009 and October 2019 were recruited for the present study. Patients who fulfilled the following criteria were included in the study: (1) having a recorded biochemical data compatible with adrCS or pitCS diagnosis, as stipulated in the Endocrine Society Clinical Guidelines3; (2) having a diagnosis of overt CS, which was established by an expert endocrinologist at the time of presentation; and (3) having a diagnosis that was retrospectively ascertained by the study authors at the time of data collection based on the documented biochemical and imaging tests, as well as management and follow-up details. As a result, a total of 64 adrCS and 50 pitCS subjects were eligible in our study.

2.3  Definition of variables

Hypertension was defined as having a diastolic blood pressure (DBP) ≥ 90 mm Hg, systolic blood pressure (SBP) ≥ 140 mm Hg, or if the patient was currently taking antihypertensive medications, as defined by the World Health Organization (WHO) in 1999.10 Regarding diabetes, subjects with a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L or those self-reported with diabetes were diagnosed with diabetes mellitus in this study.11 Lastly, dyslipidemia was defined according to the current lipids levels at the time of the study or if the patient was using anti-dyslipidemia medications. Cut-off value for hypercholesterolemia was total cholesterol (TC) ≥ 5.2 mmol/L and/or low density lipoprotein-cholesterol (LDL-C) ≥ 3.4 mmol/L. Cut-off values for hypertriglyceridemia and low high density lipoprotein-cholesterol were triglyceride (TG) ≥ 1.7 mmol/L and high density lipoprotein-cholesterol (HDL-C) < 1.04 mmol/L, respectively.12

2.4  Statistical analysis

All statistical analyses were performed using the SPSS software 25.0 for Windows (SPSS Inc., Chicago, USA). Normally and non-normally distributed continuous variables were presented as means ± standard deviation (SD) and medians (interquartile range), respectively, whereas categorical variables were presented as numbers (percentage). Differences between two groups were tested using the independent two-sample t-test, Mann-Whitney test, and Chi-squared test. All statistical tests were two-tailed, and statistical significance was defined at p < 0.05.

3  RESULTS

3.1  Characteristics of the study population

As shown in Table 1, the population consisted of 114 participants, including 64 adrCS and 50 pitCS patients. In terms of sex, females were found to suffer more frequently in both the adrCS (92.2%) and pitCS (88.0%) groups. In terms of age, pitCS patients were diagnosed at a younger age (35.40 ± 11.94 vs. 39.65 ± 11.37 years, p = 0.056) as compared to adrCS patients, although the difference was not statistically significant. Furthermore, regarding ACTH levels, lower measurements were found in adrCS patients, whereas higher measurements in pitCS patients were observed at all time points (8 AM, 4 PM, 12 AM).
TABLE 1 Characteristicsof the study population

| Characteristics | AdrCS n = 64 | pitCS n = 50 | P     | T       | Regular |
|-----------------|-------------|-------------|-------|---------|---------|
| Age (years)     | 39.65 ± 11.37 | 35.40 ± 11.94 | 0.056 | 1.931   |         |
| Female          | 59 (92.2)    | 44 (88.0)   | 0.452 | –       | –       |
| ACTH8am (pg/mL) | 1.14 ± 1.24 | 84.05 ± 40.86 | 0.001 | –16.118 | 7.2–63.3 |
| ACTH4pm (pg/mL) | 1.01 ± 0.79 | 66.81 ± 42.82 | 0.001 | –10.777 | –       |
| ACTH0am (pg/mL) | 0.99 ± 0.73 | 82.26 ± 41.16 | 0.001 | –13.556 | –       |
| Cor 8am (nmol/L)| 577.14 ± 176.99 | 835.70 ± 282.82 | 0.001 | –5.952  | 133–537 |
| Cor 4pm (nmol/L)| 559.22 ± 204.15 | 718.03 ± 295.91 | 0.001 | –3.006  | 68.2–327.0 |
| Cor 0am (nmol/L)| 499.28 ± 175.94 | 709.88 ± 291.60 | 0.001 | –4.114  | –       |
| FT4 (pmol/L)    | 13.88 ± 3.81 | 15.32 ± 3.57 | 0.092 | –1.705  | 12–22   |
| TSH (mIU/L)     | 1.33 ± 1.33 | 1.17 ± 1.04 | 0.559 | 0.587   | 0.27–4.20 |
| ALT (IU/L)      | 34.44 ± 24.42 | 36.97 ± 27.72 | 0.641 | –0.468  | 7–40    |
| AST (IU/L)      | 22.80 ± 12.05 | 23.22 ± 11.47 | 0.850 | –0.190  | 13–35   |
| Cr (μmol/L)     | 56.33 ± 13.55 | 56.80 ± 16.29 | 0.868 | –0.167  | 40–105  |

All data are expressed as mean ± standard deviation or n (%). ACTH: adrenocorticotropin; Cor: cortisol; FT4: free thyroxine; TSH: thyroid stimulating hormone; ALT: Alanine aminotransferase; AST: Aspartate transaminase; Crea: creatine.

Although serum cortisol levels were elevated significantly in both groups, the cortisol levels in pitCS patients were higher than that of adrCS patients (835.70 ± 282.82 vs. 577.14 ± 176.99 nmol/L at 8 AM, p < 0.001; 718.03 ± 295.91 vs. 559.22 ± 204.15 nmol/L at 4 PM, p < 0.001; 709.88 ± 291.60 vs. 499.28 ± 175.94 nmol/L at 12 AM, p < 0.001; respectively). Additionally, thyroid function (serum FT4 and TSH levels), liver function (serum alanine aminotransferase and aspartate transaminase levels), and renal function (serum creatinine levels) tests showed no significant differences between the two groups.

### 3.2 Metabolic profiles of adrCS and pitCS patients

In our study, the metabolic profiles of adrCS and pitCS patients were compared. As shown in Table 2, both body weight (67.67 vs. 72.88 kg, p = 0.22) and BMI (27.69 ± vs. 27.86 kg/m², p = 0.91) were similar between the two groups. Regarding blood pressure, no significant differences in either the SBP (143.39 ± 45.58 mmHg, p = 0.55) or DBP (93.53 ± 96.00 mmHg, p = 0.45) readings were found between the two groups. Regarding serum lipid profile, serum TC (6.06 ± vs. 5.83 mmol/L, p = 0.41), LDL-C (3.72 ± vs. 3.58 mmol/L, p = 0.49), HDL-C (1.49 ± 1.46 mmol/L, p = 0.77), and TG (1.80 ± 1.61 mmol/L, p = 0.31) levels were also similar between adrCS and pitCS patients. Furthermore, FPG (5.86 vs. 6.46 mmol/L, p = 0.13) and uric acid (UA) (293.53 vs. 309.46 μmol/L, p = 0.43) levels had no significant differences between the two.

### 3.3 Risk of metabolic disturbance in adrCS and pitCS patients

By definition, as shown in Table 3, both adrCS patients and pitCS patients were usually burdened with metabolic disturbance. Among the patients in our study, 83.33% had hypertension, 72.55% had high TC levels, 58.82% had high LDL-C levels, 9.80% had low HDL-C levels, 39.00% had high TG levels, and 35.96% had diabetes. However, on comparison of the two groups, only diabetes prevalence was higher in pitCS patients than...
that in adrCS patients. Additionally, no significant differences in hypertension or dyslipidemia prevalence were observed between the two groups.

4 | DISCUSSION

In this study, it was found that although pitCS patients had a higher diabetes prevalence and more serious occurrences of hypercortisolemia than adrCS patients, they had similar metabolic characteristics. To the best of our knowledge, this was the first study to focus on the metabolic differences between adrCS and pitCS patients.

The pituitary gland produces and secretes various hormones, including thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and ACTH, which have traditionally been seen as the regulators of single bodily processes, including endocrine functions. Recently, some studies have reported that the pituitary hormones also played some additional roles in physiology. For example, the TSH receptor (TSHR) was found to be expressed on hepatocytes, allowing TSH to regulate hepatic cholesterol and bile acid metabolism. Another study showed that FSH could also regulate hepatic cholesterol metabolism, wherein its inhibition reduced serum cholesterol levels. ACTH was also reported to act on osteoblastic MC2Rs, subsequently inducing vascular endothelial growth factor (VEGF) expression. Therefore, it was possible that ACTH might also have some effects on the metabolic homeostasis.

Metabolic disturbance has been the most common complication for patients with Cushing’s syndrome. A previous study showed that, aside from serious hypercortisolemia, ACTH levels differed in CS patients with different etiologies, wherein ACTH levels were higher in pitCS patients, while ACTH levels were lower or even undetectable in adrCS patients. Contrarily, in this study, we did not find obvious metabolic differences between pitCS and adrCS patients. The possible reasons were as follows: (1) the effect of hypercortisolemia was too predominant, consequently masking the effect of ACTH; (2) the effect of ACTH on metabolic dysfunction was too weak; (3) the sample size was relatively small. Therefore, further experimental studies are needed to evaluate the metabolic effect of ACTH.

It was found in this study that serum cortisol levels in pitCS patients were higher than that of adrCS patients. This was consistent with a previous study, reporting that baseline serum cortisol and urinary cortisol levels were higher in pitCS patients, as compared to adrCS patients. In contrast, another study found that there was no difference in cortisoluria severity between adrCS and pitCS patients. One possible reason for this discrepancy was that they had a high proportion of adrenocortical carcinoma patients, which might have been associated with extremely high cortisol levels. Another reason was that the adrCS patients in their study might have had very stable cortisol production rates with high levels, possibly damaging the hypothalamic CRH-producing neurons, as compared to the high amplitude ACTH and cortisol secretions in pitCS patients.

Diabetes prevalence was also found to be higher in pitCS patients than in adrCS patients, whereas no differences were found in blood pressures and lipid profiles. Contrary to our findings, no between-group differences in diabetes prevalence was reported in the ERCUSYN Study. The reason for this discrepancy was probably associated with the retrospective nature of our study, as compared to the largely prospective pro-active data collection in the European registry.

Despite the findings of our study, certain limitations were noted. First, this study utilized retrospective data collection, which has an associated risk of missing data. As such, the population was probably not fully representative of all patients who were screened and diagnosed with CS during the study period. Second, we did not enroll CS patients with ectopic ACTH secretion in this study. Lastly, the lack of a 24-hour urinary free cortisol data limited the further explorations of cortisol levels in pitCS and adrCS patients.

In conclusion, metabolic disturbance was the most common complication in CS patients. Although adrCS and pitCS had different pathogenetic mechanisms, different occurrences of serious hypercortisolemia, and different diabetes prevalences, they had similar metabolic characteristics. Therefore, further experimental studies are needed to evaluate the metabolic effects of ACTH and to validate the present study’s findings.

FUNDING
This study was supported by grants from the National Natural Science Foundation(81922016, 81870607), Shandong Provincial Natural Science Foundation (ZR2019Q25) and National Key R&D Program (2017YFC0908900) of China.

CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES

1. Barbot M, Zilio M, Scaroni C. Cushing’s syndrome: Overview of clinical presentation, diagnostic tools and complications. *Best Pract Res Clin Endocrinol Metab*. 2020;34:101380. https://doi.org/10.1016/j.beem.2020.101380

2. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100:2807-2831. https://doi.org/10.1210/jc.2015-1818

3. Ferrau F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. *Eur J Endocrinol*. 2015;173:M133-M157. https://doi.org/10.1530/EJE-15-0354

4. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. *Endocrine*. 2018;62:712. https://doi.org/10.1007/s12020-018-1300-8

5. Hirsch D, Tsvetov G, Manisterski Y, et al. Incidence of Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s. *Eur J Endocrinol*. 2018;179:41-48. https://doi.org/10.1530/EJE-16-0631

6. Nieman LK. Recent updates on the diagnosis and management of Cushing’s syndrome. *Endocrinol Metab (Seoul)*. 2018;33:139-146. https://doi.org/10.3803/EnM.2018.33.2.139

7. Valassi E, Santos A, Yaneva M, et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. *Eur J Endocrinol*. 2011;165:383-392. https://doi.org/10.1530/EJE-11-0272

8. Hirsch D, Shimon I, Manisterski Y, et al. Cushing’s syndrome: diagnosis and management. *Endocrine*. 2018;62:712-720. https://doi.org/10.1007/s12020-018-1709-y

9. Guignat L, Bertherat J. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. *Eur J Endocrinol*. 2010;163:9-13. https://doi.org/10.1530/EJE-09-0627

10. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid levels and cardiovascular disease in middle-aged and elderly Chinese individuals. *BMC Cardiovasc Disord*. 2014;14:26. https://doi.org/10.1186/1471-2261-14-26

11. Qin L, Yang Z, Gu H, et al. Association between serum uric acid and cardiovascular disease in middle-aged and elderly Chinese individuals. *BMC Cardiovasc Disord*. 2016;15:1-29. https://doi.org/10.1186/s12872-016-0297-8

12. Joint committee for guidance. Chinese guidelines for the management of dyslipidemia in adults (in Chinese). *J Geriatr Cardiol*. 2022;18:36-40. https://doi.org/10.1016/j.cdtm.2021.08.004